MOVIPREP 2.691 G — DIN 02359499
SODIUM CHLORIDE : 2.691 G POLYETHYLENE GLYCOL 3350 : 100 G ASCORBIC ACID : 4.7 G SODIUM ASCORBATE : 5.9 G SODIUM SULFATE ANHYDROUS : 7.5 G POTASSIUM CHLORIDE : 1.015 G · ARALEZ PHARMACEUTICALS CANADA INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is MOVIPREP?
MOVIPREP 2.691 G contains SODIUM CHLORIDE : 2.691 G POLYETHYLENE GLYCOL 3350 : 100 G ASCORBIC ACID : 4.7 G SODIUM ASCORBATE : 5.9 G SODIUM SULFATE ANHYDROUS : 7.5 G POTASSIUM CHLORIDE : 1.015 G. It is listed in the Health Canada Drug Product Database under DIN 02359499, held by ARALEZ PHARMACEUTICALS CANADA INC, supplied as POWDER FOR SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Aug-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MOVIPREP used for?
Cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Macrogol, Combinations cost around the world?
Macrogol, Combinations is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory); Luxembourg publishes a reimbursement. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Luxembourg | reimbursement | 20 | 20 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 3 | 5 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 3 | 3 | CZK███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
30 pack listings across 28 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Macrogol, Combinations pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Macrogol, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Macrogol, Combinations, across 8 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 4 | 1 | JAMP-ELECTROPEG, JAMP-ELECTROPEG WITH FLAVOUR PACKET, JAMPLYTE | Sourceable in Canada |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 2 | 1 | COLYTE, KLEAN-PREP | Sourceable in Canada |
| ARALEZ PHARMACEUTICALS CANADA INC | 1 | 1 | MOVIPREP | Sourceable in Canada |
| BAUSCH HEALTH, CANADA INC. | 1 | 0 | PLENVU | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.691 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | ORAL |
| Pack configuration (monograph) | One pack contains 2 transparent bags, each containing one Sachet A and one Sachet B. Sufficient for a single treatment (2 litres). |
| Storage | Reconstituted solution should be used within 24 hours; can be refrigerated. (Note: Specific powder storage temp not in provided text snippet). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Macrogol, Combinations |
|---|---|
| ATC code | A06AD65 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02359499 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2359499 |
| Brand name | MOVIPREP |
| Generic / active ingredient | SODIUM CHLORIDE : 2.691 G POLYETHYLENE GLYCOL 3350 : 100 G ASCORBIC ACID : 4.7 G SODIUM ASCORBATE : 5.9 G SODIUM SULFATE ANHYDROUS : 7.5 G POTASSIUM CHLORIDE : 1.015 G |
| Market authorization holder | ARALEZ PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Ethical |
| ATC code | A06AD65 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A06AD |
| Current status | MARKETED |
| Status date | 13-Aug-2020 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 2 litres of reconstituted solution. Can be taken as split-dose (1L evening before, 1L morning of) or full-dose (2L evening before). Drink 1L additional clear fluid.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; GI obstruction/perforation; gastric emptying disorders (e.g. gastroparesis); ileus; toxic megacolon; toxic colitis; acute surgical abdominal conditions; unconscious patients.
Warnings and precautions
Risk of fluid/electrolyte shifts, cardiac arrhythmias, seizures, and ischemic colitis. Contains aspartame (phenylalanine). Risk of G6PD deficiency hemolysis.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| COLYTE | 10.65 MG | POWDER FOR SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | 00677442 |
| JAMPLYTE | 22.96 G / 280 G | POWDER | JAMP PHARMA CORPORATION | MARKETED | 02378329 |
| JAMP-ELECTROPEG | 2.97 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | APPROVED | 02406780 |
| JAMP-ELECTROPEG WITH FLAVOUR PACKET | 2.97 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | APPROVED | 02406799 |
| JAMPLYTE | 0.76 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | APPROVED | 02368234 |
| KLEAN-PREP | 1.68 G | POWDER FOR SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | CANCELLED POST MARKET | 02147793 |
| PLENVU | 9 G | KIT ; POWDER FOR SOLUTION | BAUSCH HEALTH, CANADA INC. | CANCELLED PRE MARKET | 02550938 |
2 · Same class — other molecules in ATC A06AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Macrogol | CLARILAX · CLEARLAX · COLAXOR · COMFILAX · +17 more | 22 | 12 | Yes |
| Lactulose | CEPHULAC SYR 667MG/ML · CHRONULAC SYR · CHRONULAC SYR 667MG/ML · COMALOSE R SIROP 10GM/15ML · +20 more | 28 | 5 | Yes |
| Macrogol, Combinations | COLYTE · JAMP-ELECTROPEG · JAMP-ELECTROPEG WITH FLAVOUR PACKET · JAMPLYTE · +3 more | 8 | 3 | Yes |
| Mineral Salts In Combination | CEO-TWO BOWEL EVACUANT SUPPOSITORIES · EAU PURGATIVE RIGA · ELECTROPEG SOLUTION · GOLYTELY GI LAVAGE SOLUTION · +8 more | 13 | 1 | Yes |
| Magnesium Sulphate | EPSOM SALT PWS 100% · EPSOM SALTS · SEL D EPSOM | 6 | 0 | Not in Canada |
| Magnesium Sulphate, Combinations | AGOBYL GRANULE · AGOBYL LIQUIDE · FORMULE 1705 - LIQ | 3 | 0 | Not in Canada |
| Sodium Phosphate | EURO-PHOSPHATES SOLUTION · PHOSPHO-SODA BUFFERED SALINE LAXATIVE · PMS-PHOSPHATES SOLUTION | 3 | 0 | Not in Canada |
| Sorbitol | SORBITOL ROUGIER PWS 5GM | 1 | 0 | Not in Canada |
| Sodium Tartrate | LIMONADE RODECA | 1 | 0 | Not in Canada |
| Magnesium Oxide | MAGNESIUM CITRATE ORAL SOLUTION | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A06AB | Bisacodyl · Bisacodyl, Combinations · Cascara · Cascara, Combinations · Castor Oil · +9 more | 239 | 25 |
| A06AA | Docusate Sodium · Docusate Sodium, Combinations · Liquid Paraffin · Liquid Paraffin, Combinations | 144 | 22 |
| A06AX | Glycerol · Linaclotide · Lubiprostone · Other Laxatives · Plecanatide · +2 more | 30 | 14 |
| A06AH | Methylnaltrexone Bromide · Naloxegol | 5 | 3 |
| A06AG | Bisacodyl · Combinations · Docusate Sodium, Incl Combinations · Sodium Phosphate | 7 | 1 |
| A06AC | Ispaghula (Psylla Seeds) · Ispaghula, Combinations · Linseed · Methylcellulose · Polycarbophil Calcium · +2 more | 79 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MOVIPREP called?
The same molecule, Macrogol, Combinations, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CLENSIA | Latin | Czechia |
| MOVICOL | Latin | Morocco |
| MOVICOL PI-UK PDRE SOL.BUV. | Latin | Luxembourg |
| Pegicol Plain | Latin | South Africa |
| PLENVU | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.